Chiron Says CFO James Sulat to Resign
- Share via
Chiron Corp., the third-largest U.S. biotechnology firm, said Chief Financial Officer James Sulat will resign.
Sulat, 55, will leave the Emeryville, Calif.-based firm next month “to pursue other opportunities,” spokesman John Gallagher said, without giving details.
Chiron, which sells vaccines, blood tests and drugs, hired GlaxoSmithKline executive Howard Pien last month to take over as chief executive, succeeding Sean Lance.
David Smith, 43, vice president of finance, will take over the post on an interim basis.
Chiron shares fell 41 cents to $39.48 in Nasdaq trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
